Oxford Drug Design LimitedAnonymous Oxford, England, UK-based biotechnology company with a proprietary computational and machine learning platform, raised £2.2M in funding.
This brings the firm’s total amount of grant and equity funding to over £10M. BackersIncluded ACF Investors, o2h Ventures, Meltwind Advisory, a number returning angels and new investor and the US-based R42 Group.
LedBy Alan D. Roth, CEO, Oxford Drug DesignDesigns and develops small-molecule cancer drugs based on differentiated core competences. ItsThis platform is validated and combines AI and machine-learning methods with deep expertise. inAminoacyl-tRNA synthetases: Accelerating advances inThe development and discovery of new mechanisms of action for oncology therapeutics.
A spinout of Oxford UniversityThe company plans to use the funds for drug research and discovery, starting with a proof of concept study to validate its approach against the cancer. ItThe company will also launch a new commercial offering for its AI platform to biotechnology and pharmaceutical companies. OOD’s validated platform is inDemand from third parties is increasing in the pharmaceutical space and is already generating revenue separately from the company’s direct work inOncology drug discovery. TheInvestments will also go towards operational goals and further expansion. SeriesAn investment round this year.